Ciclomax Mini Eye Drops contain Ciclosporin 0.09% w/v, an advanced ophthalmic immunomodulator designed for the long-term management of chronic dry eye disease and ocular surface inflammation. Its higher-strength formulation supports improved tear production and sustained symptom relief.
Ciclosporin works by reducing T-cell–mediated inflammation on the ocular surface, helping to restore normal tear film function, reduce irritation, and improve overall eye comfort with continued use.
From a commercial perspective, Ciclomax Mini Eye Drops address a rapidly growing dry eye market, making them a high-value, repeat-prescription product for ophthalmologists, specialty clinics, and eye care centers.
Including Ciclomax Mini Eye Drops in your portfolio strengthens the dry eye and ocular surface disease segment, offering long-term business stability, strong prescriber loyalty, and premium positioning for PCD pharma franchise partners.